PE20220704A1 - Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos - Google Patents
Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticosInfo
- Publication number
- PE20220704A1 PE20220704A1 PE2022000148A PE2022000148A PE20220704A1 PE 20220704 A1 PE20220704 A1 PE 20220704A1 PE 2022000148 A PE2022000148 A PE 2022000148A PE 2022000148 A PE2022000148 A PE 2022000148A PE 20220704 A1 PE20220704 A1 PE 20220704A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- pyridazin
- diamino
- proapoptotic agents
- derivatives
- Prior art date
Links
- -1 3,6-DIAMINO-PYRIDAZIN-3-YL Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000861 pro-apoptotic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- JGDIBKLCOVDWSP-UHFFFAOYSA-N 2-[[6-(1,3-benzothiazol-2-ylamino)-5-methylpyridazin-3-yl]-(4-hydroxybutyl)amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]-1,3-thiazole-4-carboxylic acid Chemical compound S1C(=NC2=C1C=CC=C2)NC1=C(C=C(N=N1)N(C=1SC(=C(N=1)C(=O)O)CCCOC1=C(C=C(C=C1)C#CCNC)F)CCCCO)C JGDIBKLCOVDWSP-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19188747 | 2019-07-29 | ||
| PCT/EP2020/071179 WO2021018857A1 (en) | 2019-07-29 | 2020-07-28 | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220704A1 true PE20220704A1 (es) | 2022-05-04 |
Family
ID=67514281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000148A PE20220704A1 (es) | 2019-07-29 | 2020-07-28 | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20220289734A1 (enExample) |
| EP (1) | EP4003988A1 (enExample) |
| JP (1) | JP7646626B2 (enExample) |
| KR (1) | KR20220042182A (enExample) |
| CN (1) | CN114450283B (enExample) |
| AR (1) | AR119493A1 (enExample) |
| AU (1) | AU2020322072A1 (enExample) |
| BR (1) | BR112022001330A2 (enExample) |
| CA (1) | CA3148502A1 (enExample) |
| CL (1) | CL2021003594A1 (enExample) |
| CO (1) | CO2022000700A2 (enExample) |
| CR (1) | CR20220014A (enExample) |
| DO (1) | DOP2022000015A (enExample) |
| GE (2) | GEAP202415866A (enExample) |
| IL (1) | IL289932B2 (enExample) |
| JO (1) | JOP20220006A1 (enExample) |
| MX (1) | MX2022001161A (enExample) |
| PE (1) | PE20220704A1 (enExample) |
| PH (1) | PH12022550018A1 (enExample) |
| PY (1) | PY2039849A (enExample) |
| SA (1) | SA522431498B1 (enExample) |
| TW (1) | TWI900486B (enExample) |
| UY (1) | UY38809A (enExample) |
| WO (1) | WO2021018857A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021386367A1 (en) * | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| JP2024505562A (ja) * | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| CN119562832A (zh) | 2022-05-20 | 2025-03-04 | 诺华股份有限公司 | Met bcl-xl抑制剂抗体-药物缀合物及其使用方法 |
| AU2023271885A1 (en) | 2022-05-20 | 2024-12-12 | Les Laboratoires Servier | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| US20250387504A1 (en) | 2022-05-20 | 2025-12-25 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003059354A2 (en) * | 2001-12-21 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| WO2009020603A2 (en) * | 2007-08-08 | 2009-02-12 | The Scripps Research Institute | Upp amphiphilic alpha-helix mimetics |
| EA201001030A1 (ru) * | 2007-12-19 | 2011-02-28 | Амген Инк. | Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла |
| FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| SG11201709837RA (en) * | 2015-05-29 | 2017-12-28 | Teijin Pharma Ltd | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
-
2020
- 2020-07-27 AR ARP200102095A patent/AR119493A1/es unknown
- 2020-07-28 MX MX2022001161A patent/MX2022001161A/es unknown
- 2020-07-28 US US17/630,655 patent/US20220289734A1/en active Pending
- 2020-07-28 TW TW109125418A patent/TWI900486B/zh active
- 2020-07-28 JP JP2022505602A patent/JP7646626B2/ja active Active
- 2020-07-28 CN CN202080068042.2A patent/CN114450283B/zh active Active
- 2020-07-28 CA CA3148502A patent/CA3148502A1/en active Pending
- 2020-07-28 KR KR1020227006624A patent/KR20220042182A/ko active Pending
- 2020-07-28 IL IL289932A patent/IL289932B2/en unknown
- 2020-07-28 PY PY202002039849A patent/PY2039849A/es unknown
- 2020-07-28 CR CR20220014A patent/CR20220014A/es unknown
- 2020-07-28 UY UY0001038809A patent/UY38809A/es unknown
- 2020-07-28 AU AU2020322072A patent/AU2020322072A1/en active Pending
- 2020-07-28 GE GEAP202415866A patent/GEAP202415866A/en unknown
- 2020-07-28 GE GEAP202015866A patent/GEP20247670B/en unknown
- 2020-07-28 JO JOP/2022/0006A patent/JOP20220006A1/ar unknown
- 2020-07-28 PE PE2022000148A patent/PE20220704A1/es unknown
- 2020-07-28 BR BR112022001330A patent/BR112022001330A2/pt unknown
- 2020-07-28 WO PCT/EP2020/071179 patent/WO2021018857A1/en not_active Ceased
- 2020-07-28 PH PH1/2022/550018A patent/PH12022550018A1/en unknown
- 2020-07-28 EP EP20749833.8A patent/EP4003988A1/en active Pending
-
2021
- 2021-12-30 CL CL2021003594A patent/CL2021003594A1/es unknown
-
2022
- 2022-01-25 DO DO2022000015A patent/DOP2022000015A/es unknown
- 2022-01-26 CO CONC2022/0000700A patent/CO2022000700A2/es unknown
- 2022-01-26 SA SA522431498A patent/SA522431498B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4003988A1 (en) | 2022-06-01 |
| KR20220042182A (ko) | 2022-04-04 |
| CR20220014A (es) | 2022-03-02 |
| SA522431498B1 (ar) | 2025-04-13 |
| TW202118761A (zh) | 2021-05-16 |
| CL2021003594A1 (es) | 2022-11-18 |
| US20220289734A1 (en) | 2022-09-15 |
| DOP2022000015A (es) | 2022-05-15 |
| WO2021018857A1 (en) | 2021-02-04 |
| BR112022001330A2 (pt) | 2022-05-17 |
| JP2022542937A (ja) | 2022-10-07 |
| UY38809A (es) | 2021-02-26 |
| AU2020322072A1 (en) | 2022-02-10 |
| IL289932A (en) | 2022-03-01 |
| CA3148502A1 (en) | 2021-02-04 |
| CO2022000700A2 (es) | 2022-02-07 |
| MX2022001161A (es) | 2022-02-22 |
| IL289932B1 (en) | 2025-10-01 |
| CN114450283A (zh) | 2022-05-06 |
| GEP20247670B (en) | 2024-09-25 |
| JOP20220006A1 (ar) | 2023-01-30 |
| GEAP202415866A (en) | 2024-06-10 |
| NZ784583A (en) | 2025-02-28 |
| IL289932B2 (en) | 2026-02-01 |
| PY2039849A (es) | 2021-05-06 |
| PH12022550018A1 (en) | 2022-10-17 |
| CN114450283B (zh) | 2024-05-07 |
| TWI900486B (zh) | 2025-10-11 |
| AR119493A1 (es) | 2021-12-22 |
| JP7646626B2 (ja) | 2025-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20252677A1 (es) | Amidas de azolipiridina piridazinona como inhibidores de sos1 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20252338A1 (es) | Compuesto agonista de receptor thrb y metodo de preparacion | |
| PE20230239A1 (es) | Derivado de arilamida con actividad antitumoral | |
| PE20250674A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| AR065464A1 (es) | Derivados de nicotinamida. composiciones farmaceuticas | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
| PE20240652A1 (es) | Compuestos que inhiben la isoforma alfa de pi3k y metodos para tratar el cancer | |
| PE20241188A1 (es) | Agonistas de rxfp1 | |
| PE20241474A1 (es) | Compuestos que contienen heteroatomos y usos de estos | |
| PE20232047A1 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| PE20230235A1 (es) | Compuestos para modular la actividad de fxr y usos de los mismos | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| PE20250833A1 (es) | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead | |
| UY28688A1 (es) | Derivados de amida | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| PE20251177A1 (es) | Inhibidores heterociclicos de sik |